InvestorsHub Logo
Followers 85
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: cjgaddy post# 231106

Sunday, 08/13/2017 9:27:28 AM

Sunday, August 13, 2017 9:27:28 AM

Post# of 346714
Interesting reading this post again as now we see Dr Kathleen Mahoney from Dana Farber....tied into how Dana Farber / Dr Gordon Freeman on recent PS Targeting patents....

I also liked this one

1:35 KEYNOTE PRESENTATION: POLITICS AND REALITIES OF IO COMBINATION TRIAL DESIGN
Llew Keltner, M.D., Ph.D., CEO, EPISTAT
An acute concern of both biotechs and KOLs in IO is getting access to anti-PD-1/PD-L1 from pharma for combination trials. The current state of combination IO trials will be reviewed. The different policies of pharma companies with clinical-stage/marketed anti-PD-1/anti- PD-L1 about access to their compounds for combination trials will be compared. Trial designs and indications that might have decent luck in getting the cooperation of these companies will be suggested.

_________

Combine that with Llew Keltners video below and ties into Heat / Pelican ...where ex analyst Rahul becomes CEO ...and I wonder if Peregrine has something to tell us this week??

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=123186049
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News